Abstract
Advances in molecular biology and genetics have been used to elucidate the fundamental genetic mechanisms underlying central nervous system (CNS) diseases, yet disease-modifying therapies are currently unavailable for most CNS conditions. Antisense oligonucleotides (ASOs) are synthetic single stranded chains of nucleic acids that bind to a specific sequence on ribonucleic acid (RNA) and regulate posttranscriptional gene expression. Decreased gene expression with ASOs might be able to reduce production of the disease-causing protein underlying dominantly inherited neurodegenerative disorders. Huntington’s disease (HD), which is caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene and leads to the pathogenic expansion of a polyglutamine (PolyQ ) tract in the N terminus of the huntingtin protein (Htt), is a prime candidate for ASO therapy.
State-of-the art translational science techniques can be applied to the development of an ASO targeting HTT RNA, allowing for a data-driven, stepwise progression through the drug development process. A deep and wide-ranging understanding of the basic, preclinical, clinical, and epidemiologic components of drug development will improve the likelihood of success. This includes characterizing the natural history of the disease, including evolution of biomarkers indexing the underlying pathology; using predictive preclinical models to assess the putative gain-of-function of mutant Htt protein and any loss-of-function of the wild-type protein; characterizing toxicokinetic and pharmacodynamic effects of ASOs in predictive animal models; developing sensitive and reliable biomarkers to monitor target engagement and effects on pathology that translate from animal models to patients with HD; establishing a drug delivery method that ensures reliable distribution to relevant CNS tissue; and designing clinical trials that move expeditiously from proof of concept to proof of efficacy. This review focuses on the translational science techniques that allow for efficient and informed development of an ASO for the treatment of HD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Becker RE, Greig NH (2014) A new regulatory road-map for Alzheimer’s disease drug development. Curr Alzheimer Res 11:215–220
Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746
Zielonka D, Mielcarek M, Landwehrmeyer GB (2015) Update on Huntington’s disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord 21:169–178
Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington’s disease: what’s in the pipeline? Mov Disord 29:1434–1445
Leavitt B, Kordasiewicz TS, Landwehrmeyer B et al (2016) Discovery and early clinical development of ISIS-HTTRx the first HTT-lowering drug to be tested in patients with Huntington’s disease. Neurology 86(16 Suppl):PL01.002
Pringsheim T, Wiltshire K, Day L et al (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord 27:1083–1091
Shoulson I, Young AB (2011) Milestones in Huntington disease. Mov Disord 26:11271133
Roos RA (2010) Huntington’s disease: a clinical review. Orphanet J Rare Dis 5:40
The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983
Andrew SE, Goldberg YP, Kremer B et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 4:398–403
Squitieri F, Jankovic J (2012) Huntington’s disease: how intermediate are intermediate repeat lengths? Mov Disord 27:1714–1717
Seong IS, Ivanova E, Lee JM et al (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871–2880
Huntington G (1872) On chorea. Med Surg Reporter 26:217–321
Folstein S (1989) The psychopathology of Huntington’s disease. J Nerv Ment Dis 177:645
The Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11:136–142
Tabrizi SJ, Langbehn DR, Leavitt BR et al (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791–801
Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history biomarkers and prospects for therapeutics. Nat Rev Neurol 10:204–216
Petersen A, Bjorkqvist M (2006) Hypothalamic-endocrine aspects in Huntington’s disease. Eur J Neurosci 24:961–967
Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC (2014) The cognitive burden in Huntington’s disease: pathology phenotype and mechanisms of compensation. Mov Disord 29:673–683
Paulsen JS, Smith MM, Long JD (2013) Cognitive decline in prodromal Huntington Disease: implications for clinical trials. J Neurol Neurosurg Psychiatry 84:1233–1239
FDA Public Meeting on Patient-Focused Drug Development for Huntington’s and Parkinson’s Diseases (2015) September 22 (2015) January 22 (2017). Available from: http://www.fda.gov/Drugs/NewsEvents/ucm451807.htm
Hogarth P, Kayson E, Kieburtz K et al (2005) Interrater agreement in the assessment of motor manifestations of Huntington’s disease. Mov Disord 20:293–297
Reilmann R, Leavitt BR, Ross CA (2014) Diagnostic criteria for Huntington’s disease based on natural history. Mov Disord 29:1335–1341
Sullenger BA, Nair S (2016) From the RNA world to the clinic. Science 352:1417–1420
Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259–293
Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46–51
Chery J (2016) RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J 4:35–50
Pandey SK, Wheeler TM, Justice SL et al (2015) Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Ther 355:329–340
Rigo F, Chun SJ, Norris DA et al (2014) Pharmacology of a central nervous system delivered 2′-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther 350:46–55
Schoch KM, DeVos SL, Miller RL et al (2016) Increased 4r-tau induces pathological changes in a human-tau mouse model. Neuron 90:941–947
Wan WB, Migawa MT, Vasquez G et al (2014) Synthesis biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res 42:13456–13468
Henry ST, Kim TW, Kramer-Stickland K et al (2008) Toxicologic properties of 2′-o-methoxyethyl chimeric antisense inhibitors in animals and man. In: Crooke ST (ed) Antisense drug technology. Taylor & Francis Group, Boca Raton, pp 327–364
Viney NJ, van Capelleveen JC, Geary RS et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised double-blind placebo-controlled dose-ranging trials. Lancet 388:2239–2253
Prakash TP, Graham MJ, Yu J et al (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42:8796–8807
Hache M, Swoboda KJ, Sethna N et al (2016) Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol 31:899–906
Broaddus WC, Prabhu SS, Wu-Pong S et al (2000) Strategies for the design and delivery of antisense oligonucleotides in central nervous system. Methods Enzymol 314:121–135
Papisov MI, Belov VV, Gannon KS (2013) Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS. Mol Pharm 10:1522–1532
Jessen NA, Munk AS, Lundgaard I, Nedergaard M (2015) The glymphatic system: a beginner’s guide. Neurochem Res 40:2583–2599
Hadaczek P, Yamashita Y, Mirek H et al (2006) The “perivascular pump” driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 14:69–78
Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron 74:1031–1044
Miller TM, Pestronk A, David W et al (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1 randomised first-in-man study. Lancet Neurol 12:435–442
Chiriboga CA, Swoboda KJ, Darras BT et al (2016) Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86:890–897
Spinraza (R) [Package Insert] Biogen Inc C MA; December (2016). Available from: wwwaccessdatafdagov/drugsatfda_docs/label/(2016)/209531lblpdf. Cited 15 Jan 2017
Stanek LM, Yang W, Angus S et al (2013) Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington’s disease. J Huntingtons Dis 2:217–228
Kuemmerle S, Gutekunst CA, Klein AM et al (1999) Huntington aggregates may not predict neuronal death in Huntington’s disease. Ann Neurol 46:842–849
Moumne L, Betuing S, Caboche J (2013) Multiple aspects of gene dysregulation in Huntington’s disease. Front Neurol 4:127
Ross CA, Pantelyat A, Kogan J, Brandt J (2014) Determinants of functional disability in Huntington’s disease: Role of cognitive and motor dysfunction. Mov Disord 29:1351–1358
Banez-Coronel M, Porta S, Kagerbauer B et al (2012) A pathogenic mechanism in Huntington’s disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet 8:e1002481
Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington’s disease. Nat Rev Neurosci 6:919–930
Tsoi H, Chan HY (2013) Expression of expanded CAG transcripts triggers nucleolar stress in Huntington’s disease. Cerebellum 12:310–312
Benraiss A, Wang S, Herrlinger S et al (2016) Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun 7:11758
Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292(5521):1552–1555
Vonsattel JP, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577
Estrada-Sánchez AM, Rebec GV (2013) Role of cerebral cortex in the neuropathology of Huntington’s disease. Front Neural Circuits 7:19
Halliday GM, McRitchie DA, Macdonald V et al (1998) Regional specificity of brain atrophy in Huntington’s disease. Exp Neurol 154:663–672
Thu DC, Oorschot DE, Tippett LJ et al (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington’s disease. Brain 133:1094–1110
Wang N, Gray M, Lu XH et al (2014) Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease. Nat Med 20:536–541
Gu X, André VM, Cepeda C et al (2007) Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington’s disease. Mol Neurodegener 2:8
Rodriguez-Lebron E, Denovan-Wright EM, Nash K et al (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol Ther 12:618–633
Wang H, Lim PJ, Yin C et al (2006) Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington’s disease by ubiquitin. Hum Mol Genet 15:1025–1041
Boudreau RL, McBride JL, Martins I et al (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther 17:1053–1063
Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101:57–66
Harper SQ, Staber PD, He X et al (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A 102:5820–5825
Diaz-Hernandez M, Torres-Peraza J, Salvatori-Abarca A et al (2005) Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington’s disease. J Neurosci 25:9773–9781
Hu J, Matsui M, Gagnon KT et al (2009) Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27:478–484
Pfister EL, Kennington L, Straubhaar J et al (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington’s disease patients. Curr Biol 19:774–778
Hu J, Liu J, Corey DR (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol 17:1183–1188
Southwell AL, Skotte NH, Kordasiewicz HB et al (2014) In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther 22:2093–2106
Molero AE, Arteaga-Bracho EE, Chen CH et al (2016) Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington’s disease. Proc Natl Acad Sci U S A 113:5736–5741
Sathasivam K, Neueder A, Gipson TA et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A 110:2366–2370
Barbaro BA, Lukacsovich T, Agrawal N et al (2014) Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington’s disease. Hum Mol Genet 24:913–925
Cheng AJ, Wang JC, Van Dyke MW (1998) Self-association of G-rich oligodeoxyribonucleotides under conditions promoting purine-motif triplex formation. Antisense Nucleic Acid Drug Dev 8:215–225
Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760
Barnes G, Duyao MP, Ambrose CM et al (1994) Mouse Huntington’s disease gene homolog. Somat Cell Mol Genet 20:87–97
Chang R, Liu X, Li S, Li XJ (2015) Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy. Drug Des Devel Ther 9:2179–2188
Carroll JB, Warby SC, Southwell AL et al (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 19:2178–2185
Gray M, Shirasaki DI, Cepeda C et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182–6195
Rigo F, Seth PP, Bennett CF (2014) Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv Exp Med Biol 825:303–352
Van Dam D, De Deyn PP (2017) Non human primate models for Alzheimer’s disease-related research and drug discovery. Expert Opin Drug Discov 12:187–200
Kallman MJ (2015) Preclinical abuse potential assessment. Handb Exp Pharmacol 229:115–130
Henry SP, Geary RS, Yu R et al (2001) Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Investig Drugs 2:1444–1449
Yu R, Warren MS, Watanabe TZ et al (2016) Lack of interactions between an antisense oligonucleotide with 2′-O-(2-methoxyethyl) modifications and major drug transporters. Nucleic Acid Ther 26:111–117
Senn JJ, Burel S, Henry SP (2005) Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther 314:972–979
Henry SP, Jagels MA, Hugli TE et al (2014) Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Nucleic Acid Ther 24:326–335
Byrne LM, Wild EJ (2016) Cerebrospinal fluid biomarkers for Huntington’s disease. J Huntingtons Dis 5:1–13
Geary RS, Yu RZ, Watanabe T et al (2003) Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31:1419–1428
Yu RZ, Kim TW, Hong A et al (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide ISIS 301012 targeting human apolipoprotein B-100. Drug Metab Dispos 35:460–468
Yu RZ, Grundy JS, Henry SP et al (2015) Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2′-o-(2-methoxyethyl) modifications. Mol Ther Nucleic Acids 4:e218
European Medicines Agency (2016) Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products in EMEA/CHMP/SWP/28367/07 Rev 1 EMACfMPfHU (CHMP) Editor
Horak FB, Mancini M, Carlson-Kuhta P et al (2016) Balance and gait represent independent domains of mobility in Parkinson disease. Phys Ther 96:1364–1371
Villar R, Beltrame T, Hughson RL (2015) Validation of the Hexoskin wearable vest during lying sitting standing and walking activities. Appl Physiol Nutr Metab 40:1019–1024
Reiber H (2003) Proteins in cerebrospinal fluid and blood: barriers CSF flow rate and source-related dynamics. Restor Neurol Neurosci 21(3–4):79–96
Wild EJ, Boborwsky B, HDClarity investigators (2016) A new multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington disease. In: 11th annual CHDI HD therapeutics conference, Palm Springs, CA
Schrattenholz A, Groebe K (2007) What does it need to be a biomarker? Relationships between resolution differential quantification and statistical validation of protein surrogate biomarkers. Electrophoresis 28:1970–1979
Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Invest 125:1979–1986
Constantinescu R, Romer M, Zetterberg H et al (2009) Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington’s disease. Parkinsonism Relat Disord 15:245–248
Constantinescu R, Romer M, Zetterberg H et al (2011) Increased levels of total tau protein in the cerebrospinal fluid in Huntington’s disease. Parkinsonism Relat Disord 17:714–715
Rodrigues FB, Byrne L, McColgan P et al (2016) Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease. J Neurochem 139:22–25
Mattsson N, Insel PS, Palmqvist S et al (2016) Cerebrospinal fluid tau neurogranin and neurofilament light in Alzheimer’s disease. EMBO Mol Med 8:1184–1196
Plotkin JL, Surmeier DJ (2015) Corticostriatal synaptic adaptations in Huntington’s disease. Curr Opin Neurobiol 33:53–62
Rodrigues FB, Byrne LM, McColgan P et al (2016) Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington’s disease. PLoS One 11:e0163479
Paulsen JS, Long JD, Johnson HJ et al (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78
van Duijn E, Craufurd D, Hubers AA et al (2014) Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 85:1411–1418
Hobbs NZ, Henley NZ, Ridgway GR et al (2012) Evaluation of multi-modal multi-site neuroimaging measures in Huntington’s disease: baseline results from the PADDINGTON study. Neuroimage Clin 2:204–211
Tabrizi SJ, Reilmann R, Roos RA et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11:42–53
Hobbs NZ, Henley SM, Ridgeway GE et al (2010) The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 81:756–763
Eidelberg D (2009) Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 32:548–557
Klöppel S, Gregory S, Scheller E et al (2015) Compensation in preclinical Huntington’s disease: evidence from the Track-on HD study. EBioMedicine 2:1420–1429
Sasinowski FJ (2011) Quantum of effectiveness evidence in FDA’s approval of orphan drugs: cataloguing FDA’s flexibility in regulating therapies for persons with rare disorders. National Organization for Rare Disorders:1–27
FDA (2014) CFR-21 340510: Accelerated approval of new drugs for serious or life-threatening illnesses
Stout JC, Queller S, Baker KN et al (2014) HD-CAB: a cognitive assessment battery for clinical trials in Huntington’s disease 123. Mov Disord 29:1281–1288
Sampaio C, Borowsky B, Reilmann R (2014) Clinical trials in Huntington’s disease: interventions in early clinical development and newer methodological approaches. Mov Disord 29:1419–1428
Little TJ, Colegrave N (2016) Caging and uncaging genetics. PLoS Biol 14:e1002525
Sittig LJ, Carbonetto P, Engel KA et al (2016) Genetic background limits generalizability of genotype-phenotype relationships. Neuron 91:1253–1259
Rosas HD, Salat DH, Lee SY et al (2008) Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain 131:1057–1068
Rubinsztein DC, Orr HT (2016) Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: There may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile. Bioessays 38:977–980
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Lane, R.M. et al. (2018). Translating Antisense Technology into a Treatment for Huntington’s Disease. In: Precious, S., Rosser, A., Dunnett, S. (eds) Huntington’s Disease. Methods in Molecular Biology, vol 1780. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7825-0_23
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7825-0_23
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7824-3
Online ISBN: 978-1-4939-7825-0
eBook Packages: Springer Protocols